CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is expected to report third quarter earnings results, before market open, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.05 per share.
Looking ahead, the full year loss are expected at $ 0.25 per share on the revenues of $ 12.24 million.
Previous Quarter Performance
CASI Pharmaceuticals, Inc. announced loss for the second quarter of $ 0.09 per share, from the revenue of $ 2.67 million. According to street consensus, CASI was expected to report 2Q20 loss of $ 0.08 per share from revenue of $ 3.75 million. The bottom line results missed street analysts by $ 0.01 or 12.5 percent, at the same time, top line results fell short of analysts by $ 1.08 million or 28.8 percent.
Stock Performance
On Friday, shares of CASI Pharmaceuticals, Inc. has traded high as $ 1.99 and has cracked $ 1.89 on the downward trend, reaching $ 1.92 with volume of 284.20 thousand shares.
According to the previous trading day, closing price of $ 1.92, representing a 73.04 % increase from the 52 week low of $ 1.15 and a 44.26 % decrease over the 52 week high of $ 3.57.
The company has a market capital of $ 237.97 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
CASI Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.casipharmaceuticals.com
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The companys product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkins lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkins lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
